On May 28, 2025, Trevi Therapeutics (TRVI, Financial) received a positive endorsement from HC Wainwright & Co. as analyst Brandon Folkes initiated coverage with a "Buy" rating. This move comes as a significant development for Trevi Therapeutics, noted for its commitment to innovative therapies.
The analyst has set a price target of $21.00 USD for Trevi Therapeutics (TRVI, Financial), reflecting confidence in the company's potential growth and market position. This target price points to an optimistic outlook for investors considering TRVI shares, as no previous price target was recorded.
The coverage initiation by HC Wainwright & Co. marks a pivotal moment for Trevi Therapeutics (TRVI, Financial), underlying the stock's potential in the competitive pharmaceutical industry. Investors and market analysts will be closely monitoring TRVI following this "Buy" rating and the associated price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Trevi Therapeutics Inc (TRVI, Financial) is $19.72 with a high estimate of $29.00 and a low estimate of $11.00. The average target implies an upside of 220.17% from the current price of $6.16. More detailed estimate data can be found on the Trevi Therapeutics Inc (TRVI) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Trevi Therapeutics Inc's (TRVI, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
